Rare Site of an Inflammatory Myofibroblastic Tumor at the Epididymis: A Case Report.

IF 2.6 4区 医学 Q3 ONCOLOGY Cancer Management and Research Pub Date : 2025-01-28 eCollection Date: 2025-01-01 DOI:10.2147/CMAR.S481940
Alyssa Lange, Nicole Dominiak, Firas G Petros
{"title":"Rare Site of an Inflammatory Myofibroblastic Tumor at the Epididymis: A Case Report.","authors":"Alyssa Lange, Nicole Dominiak, Firas G Petros","doi":"10.2147/CMAR.S481940","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Inflammatory myofibroblastic tumors (IMT) are uncommon with an estimated 150-200 people being diagnosed in the US annually. We describe a healthy adult male who presented with an enlarging, painless scrotal mass. Based on current literature, only nine epididymal inflammatory myofibroblastic tumors have been reported and in this case report we describe the tenth.</p><p><strong>Case presentation: </strong>A 40-year-old Caucasian male presented with an enlarging mass near his right testicle with no associative symptoms or obvious etiology. Scrotal ultrasound showed a solid heterogenous mass with internal vascularity. Tumor markers were unremarkable for lactate dehydrogenase (LDH), beta-human chorionic gonadotropin (b-hCG), and alpha-fetoprotein (AFP). A right inguinal approach was performed. A 2-3 cm round mass adjacent to the tail of the epididymis was excised with clear margins and sent to pathology. Histology confirmed a 2.4 cm inflammatory myofibroblastic tumors with scattered positivity for smooth muscle actin, negative pancytokeratin, and negative anaplastic lymphoma kinase. Patient recovered well with no reoccurrence at this time.</p><p><strong>Conclusion: </strong>Inflammatory myofibroblastic tumors recurrence rate is <2%; however, some literature suggests higher depending on location and immunohistochemical profile. The expertise of pathologists, utilization of morphology, and immunohistological profile are all crucial in accurate diagnoses of these lesions. Literature reports some lesions have demonstrated metastatic tendencies and therefore complete excision of the mass is the recommended therapy of choice. This case highlights the increasing need to include IMT in differential diagnoses for patients presenting with painless lumps even in unlikely locations. While there is little data on epididymal tail mass recurrence rate potential, we report no current recurrence after complete excision of the mass.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"193-196"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786596/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S481940","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Inflammatory myofibroblastic tumors (IMT) are uncommon with an estimated 150-200 people being diagnosed in the US annually. We describe a healthy adult male who presented with an enlarging, painless scrotal mass. Based on current literature, only nine epididymal inflammatory myofibroblastic tumors have been reported and in this case report we describe the tenth.

Case presentation: A 40-year-old Caucasian male presented with an enlarging mass near his right testicle with no associative symptoms or obvious etiology. Scrotal ultrasound showed a solid heterogenous mass with internal vascularity. Tumor markers were unremarkable for lactate dehydrogenase (LDH), beta-human chorionic gonadotropin (b-hCG), and alpha-fetoprotein (AFP). A right inguinal approach was performed. A 2-3 cm round mass adjacent to the tail of the epididymis was excised with clear margins and sent to pathology. Histology confirmed a 2.4 cm inflammatory myofibroblastic tumors with scattered positivity for smooth muscle actin, negative pancytokeratin, and negative anaplastic lymphoma kinase. Patient recovered well with no reoccurrence at this time.

Conclusion: Inflammatory myofibroblastic tumors recurrence rate is <2%; however, some literature suggests higher depending on location and immunohistochemical profile. The expertise of pathologists, utilization of morphology, and immunohistological profile are all crucial in accurate diagnoses of these lesions. Literature reports some lesions have demonstrated metastatic tendencies and therefore complete excision of the mass is the recommended therapy of choice. This case highlights the increasing need to include IMT in differential diagnoses for patients presenting with painless lumps even in unlikely locations. While there is little data on epididymal tail mass recurrence rate potential, we report no current recurrence after complete excision of the mass.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
附睾炎性肌成纤维细胞瘤的罕见部位:1例报告。
背景:炎性肌纤维母细胞瘤(IMT)并不常见,在美国每年约有150-200人被诊断出患有此病。我们描述一个健康的成年男性谁提出了扩大,无痛性阴囊肿块。根据目前的文献,只有9例附睾炎性肌成纤维细胞肿瘤被报道,在这个病例报告中,我们描述的是第十例。病例介绍:一名40岁白人男性,右睾丸附近肿大肿块,无相关症状或明显病因。阴囊超音波显示一实性不均质肿块,内有血管。肿瘤标志物乳酸脱氢酶(LDH)、β -人绒毛膜促性腺激素(b-hCG)和甲胎蛋白(AFP)均无显著差异。右腹股沟入路。附睾尾部附近2-3厘米圆形肿块切除,边缘清晰,送病理检查。组织学证实为2.4 cm炎性肌成纤维肿瘤,平滑肌肌动蛋白分散阳性,泛细胞角蛋白阴性,间变性淋巴瘤激酶阴性。患者恢复良好,无复发。结论:炎性肌成纤维细胞瘤复发率为
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Management and Research
Cancer Management and Research Medicine-Oncology
CiteScore
7.40
自引率
0.00%
发文量
448
审稿时长
16 weeks
期刊介绍: Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include: ◦Epidemiology, detection and screening ◦Cellular research and biomarkers ◦Identification of biotargets and agents with novel mechanisms of action ◦Optimal clinical use of existing anticancer agents, including combination therapies ◦Radiation and surgery ◦Palliative care ◦Patient adherence, quality of life, satisfaction The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.
期刊最新文献
Mindfulness, Psychological Resilience, and Social Function Deficits in Young and Middle-Aged Lymphoma Patients: A Latent Profile and Mediation Analysis. Effectiveness of Neck Lymph Node Dissection for Breast Cancer Patients with Isolated Supraclavicular Nodal Recurrence. Circulating Tumor Cell PD-L1 and Peripheral Blood CD8+ T-Cell PD-1 as Dual Liquid Biopsy Biomarkers for Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer: A Retrospective Study. Evaluation of DNA Methylation in TAC1, SOX17, and RASSF1A for the Early Diagnosis of Lung Cancer. Deficient Mismatch Repair Subtypes in Vietnamese Colorectal Cancer: Clinicopathologic Associations, Predictive Modeling, and IHC-PCR Concordance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1